Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

by Auris Huen, Bradley M. Haverkos, Jasmine Zain, Ramchandren Radhakrishnan, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren Pinter-Brown, Yasuhiro Oki, Prajak J. Barde, Ajit Nair, Kasi Viswanath Routhu, Srikant Viswanadha, Swaroop Vakkalanka, Swaminathan P. Iyer
Published 2020-08-01